文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]AlF-NOTA-FAPI-04 PET/CT评估肝细胞癌肝纤维化与肿瘤负荷

Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [18F]AlF-NOTA-FAPI-04 PET/CT: a prospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-11

前瞻性单中心研究纳入57例肝细胞癌患者行[18F]AlF-NOTA-FAPI-04 PET/CT,分析肿瘤及全肝本底FAPI摄取与Child–Pugh评分、FIB-4、AFP、肿瘤大小、门静脉癌栓及CAF免疫组化标志物的关联。SUVmean与TTLF和Child–Pugh评分、肿瘤负荷及肝功能障碍相关,高SUVmean(≥6.32)或高TTLF(≥3226.31)者无进展生存与总生存更短,TTLF为独立预测因子(P=0.02)。

要点

  • FAPI PET/CT可同时评估肿瘤活性、CAF活化与肝纤维化。
  • 高SUVmean(≥6.32)或高TTLF(≥3226.31)提示生存更短。
  • TTLF为独立预后预测因子(P=0.02),本底摄取反映纤维化程度。

核心结论

  • [18F]AlF-NOTA-FAPI-04 PET/CT可整合评估肝细胞癌的肿瘤活性、CAF活化与肝纤维化,SUVmean和TTLF是稳健的预后生物标志物,本底摄取可反映纤维化严重程度。

研究设计与样本

  • 前瞻性单中心研究,57例肝细胞癌患者接受[18F]AlF-NOTA-FAPI-04 PET/CT检查,分析影像定量指标与临床、病理及免疫组化指标的关联,并用Kaplan–Meier分析、Cox回归和列线图评估预后价值。

主要发现

  • SUVmean和TTLF与Child–Pugh评分、肿瘤负荷及肝功能障碍相关。
  • SUVmean≥6.32或TTLF≥3226.31的患者无进展生存和总生存更短。
  • TTLF为独立预测因子(P=0.02)。
  • 列线图整合影像与临床变量显示良好区分度(AUC=0.875,95%CI 0.733–1.000)。
  • FIB-4分级≥3.25者TTLF和BTLF更高,FAPI摄取与FAP免疫组化染色及瘤内纤维化相关。

关键数值与推荐

  • SUVmean≥6.32或TTLF≥3226.31与更短的无进展生存和总生存相关。
  • TTLF为独立预后预测因子(P=0.02)。
  • 列线图AUC=0.875(95%CI 0.733–1.000)。
  • FIB-4分级≥3.25者TTLF和BTLF更高。

临床怎么用

  • 可将[18F]AlF-NOTA-FAPI-04 PET/CT的SUVmean和TTLF用于肝细胞癌风险分层与个体化管理,并结合本底摄取评估肝纤维化严重程度。

局限性

  • 为单中心前瞻性研究,样本量57例,结论需多中心更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hepatocellular carcinoma (HCC) commonly develops in the setting of cirrhosis, highlighting the need for reliable noninvasive biomarkers to assess both tumor burden and hepatic function. Conventional [18F]FDG PET/CT has limited sensitivity for HCC. In contrast, FAPI PET/CT targets fibroblast activation protein (FAP), enabling visualization of cancer-associated fibroblasts (CAFs) and stromal fibrosis, and offering a novel imaging strategy for HCC. METHODS: In this prospective single-center study, 57 HCC patients underwent [18F]AlF-NOTA-FAPI-04 PET/CT. Quantitative tumor variables included SUVmax, SUVmean, metabolic tumor volume, and total lesion FAP expression (TLF). Total liver segmentation yielded the Total liver SUVmean (TSUVmean) and Total liver FAP expression (TTLF); Boolean operations were used to derive background metrics (BSUVmean, BTLF). Associations with Child–Pugh score, FIB-4 fibrosis index, alpha-fetoprotein (AFP), tumor size, portal vein tumor thrombosis (PVTT), and CAF immunohistochemical markers were analyzed. Prognostic value of imaging and clinical variables was assessed by Kaplan–Meier analysis, Cox regression, and a nomogram. RESULTS: SUVmean and TTLF were associated with Child–Pugh score, tumor burden, and liver dysfunction. Patients with higher SUVmean (≥ 6.32) or TTLF (≥ 3226.31) had shorter progression-free and overall survival, and TTLF remained an independent predictor (P = 0.02). Our nomogram integrating imaging and clinical variables showed good discrimination (AUC = 0.875, 95% CI 0.733–1.000). Background uptake reflected fibrosis severity, as patients with FIB-4 grade ≥ 3.25 had higher TTLF and BTLF. FAPI uptake correlated with FAP immunohistochemical staining and intratumoral fibrosis, suggesting that it may serve as a noninvasive surrogate of tumor stromal activity. CONCLUSION: [18F]AlF-NOTA-FAPI-04 PET/CT provides an integrated assessment of tumor activity, CAF activation, and hepatic fibrosis in HCC. SUVmean and TTLF are robust prognostic biomarkers and background uptake captures fibrosis severity, supporting its role as a noninvasive tool for risk stratification and personalized management.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang C, Xu K, Li W, et al. Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [18F]AlF-NOTA-FAPI-04 PET/CT: a prospective study. Eur J Nucl Med Mol Imaging. 2026. PMID: 41670631. doi:10.1007/s00259-026-07804-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。